Hemolytic anemia post high‐dose IVIG in Kawasaki disease: Impact of inflammation and iron status on outcomes
Pediatrics International · 2026-01 · 68 (1)
DOI: 10.1111/ped.70370 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatrics International, online erschienen am 16.03.2026. Verfasst von Mucheleng'anga Lusungu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Chungnam National University Hospital, College of Medicine, Chungnam National University, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Mucocutaneous Lymph Node Syndrome, Immunoglobulins, Intravenous, Anemia, Hemolytic, Immunologic Factors. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
As an initial therapy for Kawasaki disease, high‐dose intravenous immunoglobulin (IVIG) is recommended. It is known that intravenous immunoglobulins are associated with hemolytic anemia. However, little is known about hemolytic anemia in Kawasaki disease (KD) patients treated with IVIG. This study was designed to investigate the incidence of hemolytic anemia and factors associated with the development of hemolysis in KD patients treated with IVIG.
Methods
We performed a 3‐year single‐center prospective study enrolling 105 KD patients treated with IVIG from January 2021 to May 2024 at Chungnam National University Hospital. Clinical characteristics and laboratory data were collected and analyzed. Hemolytic anemia was defined as a drop in hemoglobin levels or worsening of anemia after IVIG infusion greater than or equal to 2 g/dL with supporting biochemical studies.
Results
Fifteen percent of KD patients (16/105) developed hemolytic anemia post‐IVIG. Increased IVIG dose, prolonged duration of fever, high pre‐ and post‐IVIG white blood cell counts, non‐O blood groups, NT‐ProBNP, and refractory KD were significantly associated with the hemolysis group ( p < 0.05). However, erythrocyte sedimentation rate (ESR), C‐reactive protein, and iron deficiency anemia parameters were not significant between the two groups.
Conclusion
This study suggests that a non‐O blood group, a higher cumulative IVIG dose, elevated NT‐ProBNP levels, and increased white blood cell counts may be associated with an increased risk of hemolysis following IVIG therapy. These findings are hypothesis‐generating and support the need for closer monitoring and further investigation in larger, controlled studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Chungnam National University Hospital, College of Medicine, Chungnam National University, Daejeon, Republic of Korea.
- Department of Pediatrics, Chungnam National University Hospital, Sejong, Republic of Korea.
ORCID-Profile: Mucheleng'anga Lusungu, Youna Park, Bae Eun Young, Choi Ah Young, Geena Kim, Yeon Jung Lim, Hong Ryang Kil
Zitieren
APA
Lusungu, M., Park, Y., Young, B. E., Young, C. A., Kim, G., Lim, Y. J., & Kil, H. R. (2026). Hemolytic anemia post high‐dose IVIG in Kawasaki disease: Impact of inflammation and iron status on outcomes. Pediatrics International, 68(1). https://doi.org/10.1111/ped.70370
Vancouver
Lusungu M, Park Y, Young BE, Young CA, Kim G, Lim YJ, et al. Hemolytic anemia post high‐dose IVIG in Kawasaki disease: Impact of inflammation and iron status on outcomes. Pediatrics International. 2026;68(1). doi:10.1111/ped.70370
BibTeX
@article{Lusungu2026,
author = {Lusungu, Mucheleng'anga and Park, Youna and Young, Bae Eun and Young, Choi Ah and Kim, Geena and Lim, Yeon Jung and Kil, Hong Ryang},
title = {Hemolytic anemia post high‐dose IVIG in Kawasaki disease: Impact of inflammation and iron status on outcomes},
journal = {Pediatrics International},
year = {2026},
volume = {68},
number = {1},
doi = {10.1111/ped.70370}
}
EUVIMED